Table 1. Patient Characteristics.
| No. | % | ||
|---|---|---|---|
| Total number | 404 | 100 | |
| Gender | Female | 185 | 46 |
| Male | 219 | 54 | |
| Age in years | Median (Range) | 59 (18–87) | |
| Stage a | I | 210 | 52 |
| II/IIE | 131 | 32 | |
| I/extranodal | 44 | 11 | |
| II/extranodal | 19 | 5 | |
| Bulky | Not bulky | 352 | 87 |
| Bulky(max diameter ≥ 6cm) b | 52 | 13 | |
| FLIPI c | 0–1 | 359 | 89 |
| 2–3 | 33 | 8 | |
| Extranodal involvement | Absent | 338 | 84 |
| Present | 66 | 16 | |
| B symptoms | Absent | 385 | 95 |
| Present | 19 | 5 | |
| WHO | 0 | 257 | 64 |
| 1 | 143 | 35 | |
| 2–3 | 4 | 1 | |
| Involved site | Supradiaphragmatic | 196 | 48 |
| Subdiaphragmatic | 208 | 52 | |
| Treatment | RT | 214 | 53 |
| CT | 63 | 16 | |
| CRT | 64 | 16 | |
| OBS | 63 | 15 | |
| Involved organ in I/extranodal | Skin | 12 | |
| Stomach/Intestine | 12 | ||
| Salivary gland | 9 | ||
| Thyroid gland | 4 | ||
| Oral/Nasal | 2 | ||
| Muscle/Tendon | 2 | ||
| Prostate/Testicle | 2 | ||
| Eye | 1 | ||
| Total | 44 | ||
| Involved organ in II/extranodal | Skin | 6 | |
| Oral/Nasal | 5 | ||
| Parotid gland | 3 | ||
| Stomach | 2 | ||
| Bone | 2 | ||
| Kidney | 1 | ||
| Total | 19 | ||
Comments:
a Stage: II/IIE: Stage II with or without extranodal extension; I/extranodal: Stage I with primary extranodal involvement; II/extranodal: Stage II with primary extranodal involvement.
b Maximum tumor diameter.
c FLIPI was missing for 12 (3%) of patients.
Abbreviations: RT: Radiotherapy, CT: Chemotherapy, CRT: Chemotherapy followed by Radiotherapy, OBS: Observation without treatment.